| Primary information |
|---|
| sequence ID | Seq_1757 |
| Peptide sequence | EETKENEGFTVTAEG |
| CancerPDF_ID | CancerPDF_ID944, CancerPDF_ID8786, CancerPDF_ID9602, |
| PMID | 19795908,24694173,21533267 |
| Protein Name | Complement C3,Complement C3 (Fragment),Complement C3 |
| UniprotKB Entry Name | CO3_HUMAN,CO3_HUMAN,CO3_HUMAN |
| Fluid | Plasma,Ascites fluid,Serum |
| M/Z | 820.86,NA,820.86 |
| Charge | 2,1,2 |
| Mass (in Da) | NA,NA,NA |
| fdr | NA,NA,NA |
| Profiling Technique | LC-MS,LTQ-Orbitrap XL,LC-MS |
| Peptide Identification technique | MALDI-TOF/TOF,X tandem for peptide identification,LC/MS/MS |
| Quantification Technique | LC-MRM (multiple reaction monitoring),NA,Multiple Reaction Monitoring |
| Labelled/Label Free | Labelled,Label Free,Label Free |
| FDR | less than 7%,NA,1.49 |
| CancerPDF_ID | CancerPDF_ID944, CancerPDF_ID8786, CancerPDF_ID9602, |
| p-Value | NA,NA,NA |
| Software | FlexAnalysis 3.0 and Biotools 3.0 software,"X tandem for peptide identification,Scaffold 2 software for any modification analysis",MASCOT |
| Length | 15,15,15 |
| Cancer Type | Ductal adenocarcinoma of the pancreas (DAP),Ovarian cancer,Lung adenocarcinoma |
| Database | NCBI refseq Protein Database,IPI00783987,Swissprot Database (57.4) |
| Modification | NA,NA,NA |
| Number of Patients | "42 normal, 28 patients",3 ovarian cancer patient and 3 non cancerous control,62 lung adenocarcinoma and 30 healthy control |
| Regulation | NA,Uniquely expressed in ovarian cancer patient,"Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" |
| Validation | NA,NA,MRM-based validation of 19 candidates |
| Sensitivity | NA,NA,NA |
| Specificity | NA,NA,NA |
| Accuracy | NA,NA,NA |
| Peptide Atlas | NA |
| IEDB | |